Roussou Euthalia, Bouraoui Aicha
Department of Rheumatology and Rehabilitation, Barking Havering and Redbridge University Hospitals NHS Trust, King George Hospital, Barley Lanes, London, UK.
Eur J Rheumatol. 2017 Mar;4(1):1-10. doi: 10.5152/eurjrheum.2017.1608. Epub 2017 Mar 1.
With the aim of assessing the response to treatment with conventional disease-modifying anti-rheumatic drugs (DMARDs) used in patients with psoriatic arthritis (PsA), data on methotrexate, sulfasalazine (SSZ), and leflunomide were analyzed from baseline and subsequent follow-up (FU) questionnaires completed by patients with either PsA or other spondyloarthritides (SpAs).
A single-center real-life retrospective analysis was performed by obtaining clinical data via questionnaires administered before and after treatment. The indices used were erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) level, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Function Index (BASFI), wellbeing (WB), and treatment effect (TxE). The indices measured at baseline were compared with those measured on one occasion in a FU visit at least 1 year later.
A total of 73 patients, 51 with PsA (mean age 49.8±12.8 years; male-to-female ratio [M:F]=18:33) and 22 with other SpAs (mean age 50.6±16 years; M:F=2:20), were studied. BASDAI, BASFI, and WB displayed consistent improvements during FU assessments in both PsA patients and controls in comparison to baseline values. SSZ exhibited better efficacy as confirmed by TxE in both PsA patients and controls. ESR and CRP displayed no differences in either the PsA or the SpA group between the cases before and after treatment.
Real-life retrospective analysis of three DMARDs used in PsA (and SpAs other than PsA) demonstrated that all three DMARDs that were used brought about improvements in BASDAI, BASFI, TxE, and WB. However, the greatest improvements at FU were seen with SSZ use in both PsA and control cohorts.
为评估银屑病关节炎（PsA）患者使用传统病情缓解抗风湿药物（DMARDs）的治疗反应，对PsA或其他脊柱关节炎（SpA）患者在基线及后续随访（FU）问卷中有关甲氨蝶呤、柳氮磺吡啶（SSZ）和来氟米特的数据进行分析。
通过治疗前后发放问卷获取临床数据，进行单中心真实生活回顾性分析。所使用的指标包括红细胞沉降率（ESR）、C反应蛋白（CRP）水平、巴斯强直性脊柱炎疾病活动指数（BASDAI）、巴斯强直性脊柱炎功能指数（BASFI）、健康状况（WB）和治疗效果（TxE）。将基线时测量的指标与至少1年后FU访视时单次测量的指标进行比较。
共研究了73例患者，其中51例为PsA患者（平均年龄49.8±12.8岁；男女比例[M:F]=18:33），22例为其他SpA患者（平均年龄50.6±16岁；M:F=2:20）。与基线值相比，在FU评估期间，PsA患者和对照组的BASDAI、BASFI和WB均呈现持续改善。TxE证实，SSZ在PsA患者和对照组中均显示出更好的疗效。ESR和CRP在PsA组或SpA组的治疗前后病例之间均无差异。
对PsA（以及PsA以外的SpA）使用的三种DMARDs进行的真实生活回顾性分析表明，所使用的所有三种DMARDs均使BASDAI、BASFI、TxE和WB得到改善。然而，在FU时，PsA和对照组使用SSZ的改善最为明显。
